MAPT and tauopathy: To determine whether this phenomenon can be detected in mouse models of tauopathy, we next assessed class IIa HDAC levels in the widely-used PS19 tau transgenic mice, which overexpress P301S tau under the prion promotor and display widespread NFTs, gliosis and cognitive decline by six months of age [29].